Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;24(5):393-401.
doi: 10.1016/j.nmd.2013.12.012. Epub 2014 Jan 11.

Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression

Affiliations

Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression

R J Willcocks et al. Neuromuscul Disord. 2014 May.

Abstract

Duchenne muscular dystrophy (DMD) is characterized by an increased muscle damage and progressive replacement of muscle by noncontractile tissue. Both of these pathological changes can lengthen the MRI transverse proton relaxation time (T2). The current study measured longitudinal changes in T2 and its distribution in the lower leg of 16 boys with DMD (5-13years, 15 ambulatory) and 15 healthy controls (5-13years). These muscles were chosen to allow extended longitudinal monitoring, due to their slow progression compared with proximal muscles in DMD. In the soleus muscle of boys with DMD, T2 and the percentage of pixels with an elevated T2 (⩾2SD above control mean T2) increased significantly over 1year and 2years, while the width of the T2 histogram increased over 2years. Changes in soleus T2 variables were significantly greater in 9-13years old compared with 5-8years old boys with DMD. Significant correlations between the change in all soleus T2 variables over 2years and the change in functional measures over 2years were found. MRI measurement of muscle T2 in boys with DMD is sensitive to disease progression and shows promise as a clinical outcome measure.

Keywords: 30 Foot walk; Duchenne muscular dystrophy; Magnetic resonance imaging; Transverse relaxation time.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Top: T2-weighted images acquired in a boy with DMD (aged 9.9 years at baseline) over two years, showing increasing areas of hyperintensity over time. Bottom left: T2-weighted image from a 10 year old control boy, with homogeneous signal intensity in muscle. Bottom right: Longitudinal changes in the soleus T2 histogram in the above subject, illustrating changes in the histogram with disease progression. The rightward shift is captured by the mean T2 value, while the broadening of the histogram is captured by the FWHM and FWQM (dashed lines). The upper boundary of the T2 of healthy muscle (defined as the 95th percentile of the control T2 histogram) is represented by the vertical dotted line.
Figure 2
Figure 2
Individual mean soleus T2 data plotted against age. For clarity, only baseline and 2 year points are shown. T2 increased with time in boys with DMD at all ages, but changes were considerably more pronounced after approximately 9 years old. The boy diagnosed with BMD is shown in grey. Solid and dashed lines across the bottom of the plot represent the control mean and 95% confidence intervals.
Figure 3
Figure 3
Longitudinal changes in mean T2 (A), elevated pixels (B), FWHM (C), and FWQM (D) in the soleus muscle. Solid horizontal line represents the control mean, while the dashed horizontal line represents the 95% confidence intervals around the control mean.
Figure 4
Figure 4
Longitudinal changes in mean T2 in the peroneal, soleus, and tibialis anterior muscles.
Figure 5
Figure 5
Correlation between the change in T2 variables in the soleus (over two years) and the change in 30 ft walk time (over two years). Two boys lost ambulation before or during the study, and were assigned an arbitrary maximum value to permit analysis using Spearman rank correlations. The two nonambulatory boys are represented by open circles.

References

    1. Desguerre I, Christov C, Mayer M, et al. Clinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up. PLoS One. 2009;4:e4347. - PMC - PubMed
    1. Fraser LK, Childs AM, Miller M, et al. A cohort study of children and young people with progressive neuromuscular disorders: clinical and demographic profiles and changing patterns of referral for palliative care. Palliat Med. 2011 - PubMed
    1. Pichavant C, Aartsma-Rus A, Clemens PR, et al. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther. 2011;19:830–40. - PMC - PubMed
    1. Porter JD, Khanna S, Kaminski HJ, et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet. 2002;11:263–72. - PubMed
    1. Cros D, Harnden P, Pellissier JF, Serratrice G. Muscle hypertrophy in Duchenne muscular dystrophy. A pathological and morphometric study. J Neurol. 1989;236:43–7. - PubMed

Publication types